Möchten Sie immer auf dem neuesten Stand bleiben?

TEMPE, Ariz., June 25, 2026 (GLOBE NEWSWIRE) -- Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms...

Kither Biotech announces the successful completion of its Phase 1 clinical study of KIT2014 in healthy participants.

STOCKHOLM, June 18, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) is proud to announce that an oral presentation was conducted for the Black Swan Research Initiative’s® (BSRI)...

First patient dosed in FPWR-supported Phase 2a trial of CSTI-500 for hyperphagia and neurobehavioral symptoms in PWS.

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – ...

Completion of patient dosing in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate...

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics,...

Alkeus Pharmaceuticals announces first patient dosed in pivotal global Phase 3 NORTHSTAR Study of oral gildeuretinol in Stargardt disease.

OMN6: First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept

First-in-class oral ERAP1 inhibitor shows 13–36% ORR across 6 solid tumor types in anti-PD-1 resistant patients